Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis-Are We Getting Closer to Personalised Medicine?

Current rheumatology reports - 1 Apr 2017

Roszkiewicz Justyna, Smolewska Elzbieta

Abstract excerpt

PURPOSE OF REVIEW: Methotrexate (MTX) is the most widely used disease-modifying antirheumatic drug (DMARD) in paediatric rheumatology and the mainstay in the therapy of juvenile idiopathic arthritis (JIA). Despite its common use, about 30% of children fail to respond to this medicine that results in potentially irreversible joint damage. RECENT FINDINGS: No clinical biomarker that would predict the outcome of MTX...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Juvenile

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Drug Monitoring

Share to Genetic Predisposition to Disease

Share to Methotrexate

Share to Precision Medicine

Share to Treatment Outcome

Source

Identifiers

PMID: 28361333
DOI: 10.1007/s11926-017-0646-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis-Are We Getting Closer to Personalised Medicine?PMID 28361333Read ↗

Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy.Semantic proximity Read ↗

Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases.Semantic proximity Read ↗

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis.Semantic proximity Read ↗

Current developments in the use of biomarkers for juvenile idiopathic arthritis.Semantic proximity Read ↗

Genetic determinants of methotrexate treatment efficacy in patients with juvenile idiopathic arthritisSemantic proximity Read ↗

Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype.Semantic proximity Read ↗

Advancements and progress in juvenile idiopathic arthritis: A Review of pathophysiology and treatment.Semantic proximity Read ↗

The genetics of juvenile idiopathic arthritis: current understanding and future prospects.Semantic proximity Read ↗

Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis.Semantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.Semantic proximity Read ↗

Diagnosis and classification of juvenile idiopathic arthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.